Suchergebnisse - "Juvekar, Ashish"

PubPharm (21)

1

Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models

enthalten in: Immunotherapy | 2021

von Huarte, E. | Peel, M. | Juvekar, A. | +8

2

Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Huarte, E. | O'Connor, R. | Peel, M. | +9

3

Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases

enthalten in: European journal of pharmacology | 2020

von Covington, M. | He, X. | Scuron, M. | +19

4

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

enthalten in: Clinical immunology (Orlando, Fla.) | 2020

von Yeleswaram, S. | Smith, P. | Burn, T. | +5

5

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2016

von Juvekar, A. | Hu, H. | Yadegarynia, S. | +13

6

Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer

enthalten in: Nature cell biology | 2016

von Lien, E. | Lyssiotis, C. | Juvekar, A. | +4

CommentIn: Cell Death Differ. 2016 Aug;23(8):1269-70. - PMID 27315299

7

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton

enthalten in: Cell | 2016

von Hu, H. | Juvekar, A. | Lyssiotis, C. | +15

8

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion

Erschienen: 2016

von Juvekar, A. | Hu, H. | Yadegarynia, S. | +13

9

Phosphoinositide 3-Kinase regulates glycolysis through mobilization of Aldolase A from the actin cytoskeleton

enthalten in: Cancer & metabolism | 2014

von Hu, H. | Juvekar, A. | Lyssiotis, C. | +5

10

Closing escape routes : inhibition of IL-8 signaling enhances the anti-tumor efficacy of PI3K inhibitors

enthalten in: Breast cancer research : BCR | 2013

von Juvekar, A. | Wulf, G.